195 related articles for article (PubMed ID: 18439674)
1. JAK2-V617F and BCR-ABL--double jeopardy?
Krämer A
Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
[No Abstract] [Full Text] [Related]
2. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
Go RS
Leukemia; 2007 Sep; 21(9):2051; author reply 2052. PubMed ID: 17597806
[No Abstract] [Full Text] [Related]
3. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
[No Abstract] [Full Text] [Related]
4. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
5. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
[No Abstract] [Full Text] [Related]
6. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.
Bader G; Dreiling B
J Investig Med High Impact Case Rep; 2019; 7():2324709619832322. PubMed ID: 30803277
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.
de Conchon MRM; Costa JL; Novaes MMY; Dorlhiac-Llacer PE; de Alencar Fischer Chamone D; Bendit I
Int J Hematol; 2008 Sep; 88(2):243-245. PubMed ID: 18626727
[No Abstract] [Full Text] [Related]
8. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V
Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144
[No Abstract] [Full Text] [Related]
9. Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.
Park SH; Chi HS; Cho YU; Jang S; Park CJ; Kim DY; Lee JH; Lee KH
Ann Lab Med; 2013 May; 33(3):229-32. PubMed ID: 23667855
[No Abstract] [Full Text] [Related]
10. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
Pingali SR; Mathiason MA; Lovrich SD; Go RS
Clin Lymphoma Myeloma; 2009 Oct; 9(5):E25-9. PubMed ID: 19858050
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
[TBL] [Abstract][Full Text] [Related]
12. Insights into JAK2-V617F mutation in CML.
Bocchia M; Vannucchi AM; Gozzetti A; Guglielmelli P; Poli G; Crupi R; Defina M; Bosi A; Francesco L
Lancet Oncol; 2007 Oct; 8(10):864-6. PubMed ID: 17913657
[No Abstract] [Full Text] [Related]
13. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
[TBL] [Abstract][Full Text] [Related]
14. Insights into JAK2-V617F mutation in CML.
Büsche G; Hussein K; Bock O; Kreipe H
Lancet Oncol; 2007 Oct; 8(10):863-4. PubMed ID: 17913656
[No Abstract] [Full Text] [Related]
15. A Patient With BCR-ABL and JAK2 V617F Double-Positive Myeloproliferative Neoplasm With Overlapping Clinical Phenotypes.
Wang Y; Xia J; Wu X; Hu Y
Am J Med Sci; 2015 Jul; 350(1):68-9. PubMed ID: 25798831
[No Abstract] [Full Text] [Related]
16. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
[TBL] [Abstract][Full Text] [Related]
17. [Advance of study on JAK2 V617F in myeloproliferative disorders -- review].
Xu YY; Li HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):238-42. PubMed ID: 19236788
[TBL] [Abstract][Full Text] [Related]
18. The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.
McCarron SL; Haslam K; Crampe M; Langabeer SE
Lab Hematol; 2012 Dec; 18(4):20-1. PubMed ID: 23253862
[No Abstract] [Full Text] [Related]
19. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.
Cross NC; Daley GQ; Green AR; Hughes TP; Jamieson C; Manley P; Mughal T; Perrotti D; Radich J; Skoda R; Soverini S; Vainchenker W; Verstovsek S; Villeval JL; Goldman JM
Leukemia; 2008 Nov; 22(11):1975-89. PubMed ID: 19002192
[No Abstract] [Full Text] [Related]
20. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation.
Nadarajan VS; Ang CH; Bee PC
Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]